11/25
08:14 am
acrs
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
08:00 am
acrs
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/12
01:23 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/7
01:12 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
06:59 am
acrs
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/29
07:30 am
acrs
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
Low
Report
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
10/20
08:08 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
10/12
12:08 pm
acrs
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth? [Yahoo! Finance]
Low
Report
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth? [Yahoo! Finance]
10/3
02:37 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/30
07:00 am
acrs
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
Low
Report
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
9/22
02:34 am
acrs
Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight [Yahoo! Finance]
Low
Report
Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight [Yahoo! Finance]
9/21
08:37 am
acrs
With 56% institutional ownership, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a favorite amongst the big guns [Yahoo! Finance]
Low
Report
With 56% institutional ownership, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a favorite amongst the big guns [Yahoo! Finance]
9/9
07:13 am
acrs
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress [Yahoo! Finance]
Low
Report
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress [Yahoo! Finance]
9/9
07:00 am
acrs
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
Low
Report
Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress